Leadership & Pay ·
Nyxoah appoints Liam Kelly as CEO to accelerate U.S. commercial traction for Genio sleep apnea therapy
NYXHNyxoah SA
Nyxoah SA announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding outgoing CEO Olivier Taelman. The leadership transition aims to accelerate U.S. commercial traction for Genio, a neuromodulation therapy for Obstructive Sleep Apnea following its FDA approval and launch in the United States. Liam Kelly brings over 25 years of MedTech experience, previously serving as Chairman, President, and CEO of Teleflex Incorporated until January 2026. Nyxoah is a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea through neuromodulation.